Introduction {#s01}
============

Since diverging from plants over one billion years ago, fungi have coevolved with animals as an integral part of all ecosystems ([@bib50]; [@bib34]). Like bacteria, fungi are a component of the microbiota at barrier surfaces in mammals, where emerging studies suggest they play an important role in shaping host immunity and tissue homeostasis ([@bib4]; [@bib16]). Alterations in intestinal fungal composition and dysbiosis have been associated with human inflammatory disorders, such as inflammatory bowel disease (IBD), colorectal cancer, and allergy ([@bib44]; [@bib56]; [@bib8]), in which mutations or deficiencies in fungal recognition receptors or downstream signaling pathways have been shown to substantially influence disease severity ([@bib17]; [@bib51], [@bib52]; [@bib28]; [@bib32]). Nevertheless, how fungi interact with the mammalian host and the molecular mechanisms mediating fungal recognition and resultant host responses remains incompletely defined.

Chitin, a linear polysaccharide of β-(1,4)-linked N-acetylglucosamine (GlcNAc), is one of the most abundant natural biopolymers, and is an essential structural component of crustaceans, insects, nematodes, protozoa, and fungi. Since it is absent in vertebrates, chitin is recognized as a pathogen-associated molecular pattern and targeted by the mammalian immune system ([@bib5]; [@bib13]). Exposure to chitin can induce mammalian immune responses, often resembling responses associated with helminth infection and allergic inflammation ([@bib38]; [@bib40]; [@bib48]). FIBCD1, a transmembrane protein tetramer that structurally resembles the ficolin family of pattern recognition receptors, binds chitin and other acetylated structures with high affinity in vitro ([@bib42]; [@bib47]). Unlike the ficolins, FIBCD1 does not bind to conventional microbe-associated molecular patterns, such as LPS, peptidoglycan, lipoteichoic acid, or β-glucan, yet it appears to bind chitin, recognize chitin-rich regions of *Aspergillus fumigatus* and modulate cellular responses to fungal cell wall components in a human lung epithelial cell line in vitro ([@bib42]; [@bib20]).

Results and discussion {#s02}
======================

The biological functions of FIBCD1 in vivo are currently poorly understood; however, previous immunohistochemical studies in human tissues suggest that FIBCD1 expression is restricted to cells of the epithelial lineage, particularly at the intestinal barrier surface ([@bib49]). To examine this further, we isolated small intestine (SI) and colon from healthy human organ donors and assessed the expression of FIBCD1 in freshly isolated live human cells by quantitative RT-PCR and flow cytometry. In both human SI and colon, *FIBCD1* expression was highest in the epithelial compartment compared with intact tissue, lamina propria (LP), or remaining stroma ([Fig. 1 A](#fig1){ref-type="fig"}). Moreover, *FIBCD1* expression was restricted to sort-purified human CD45^−^CD326^+^ intestinal epithelial cells (IECs) when compared with the hematopoietic CD45^+^CD326^−^ cell population ([Fig. 1 B](#fig1){ref-type="fig"}). Flow cytometry analysis further confirmed a highly specific surface expression of FIBCD1 on the CD45^−^CD326^+^ IEC population ([Fig. 1 C](#fig1){ref-type="fig"}). Together, these findings identify that FIBCD1 is a membrane protein specifically expressed on epithelial cells lining the human intestinal tract.

![**FIBCD1 is expressed on the surface of human IECs, and this can be recapitulated in novel transgenic mice. (A)** Analysis of *FIBCD1* expression in fractionated SI and colon from healthy human donors (*n* = 4--6 samples per group). **(B)** Gating strategy and analysis of *FIBCD1* expression in CD45^+^CD326^−^ hematopoietic cells and CD45^−^CD326^+^ epithelial cells sorted from human colon (*n* = 3 samples per group). **(C)** Representative histograms of FIBCD1 expression in CD45^+^CD326^−^ hematopoietic cells and CD45^−^CD326^+^ epithelial cells from human SI and colon. **(D)** Expression of *Fibcd1* in SI and colon mouse tissues from WT and *Fibcd1*^Tg^ (Tg) littermates (*n* = 6 samples per group). **(E)** Representative histograms depicting FIBCD1 expression in CD45^+^CD326^−^ hematopoietic cells and CD45^−^CD326^+^ epithelial cells from SI and colon of WT and Tg littermates. **(F)** Representative immunofluorescence staining for FIBCD1 in SI and colon from WT and Tg littermates. Blue, DAPI; magenta, FIBCD1. Scale bars, 100 µm. **(G)** Representative pull-down experiment showing acetyl-group-specific and Ca^2+^-dependent binding of soluble recombinant mFIBCD1 ectodomain to chitin. Results in A and B are pooled data based on three to six independently collected samples from healthy human donors. Data in C--G are representative of at least three independently performed experiments with similar results. Statistics: Data are presented as mean ± SEM where dots represent individual mice. One-way ANOVA followed by Tukey post hoc test was used to analyze results in A and B, and unpaired Student's *t* test was used to analyze data in D. \*\*, P \< 0.01 and \*\*\*\*, P \< 0.0001.](JEM_20182244_Fig1){#fig1}

In mice, expression of *Fibcd1* mRNA is detectable in intestinal tissues, yet below the limit of detection in sorted cell populations (Fig. S1, A and B). Thus, to investigate the potential in vivo functional significance of FIBCD1 in intestinal tissues, we developed a gain-of-function transgenic mouse model (*Fibcd1*^Tg^) using the *Villin* promoter, previously shown to drive IEC-specific expression in mouse intestinal tissues ([@bib36]). Expression of *Fibcd1* in SI and colon from *Fibcd1*^Tg^ mice was initially verified by quantitative RT-PCR ([Fig. 1 D](#fig1){ref-type="fig"}), and further analyses by flow cytometry and immunofluorescence microscopy confirmed specific staining for FIBCD1 on CD45^−^CD326^+^ IECs lining the intestinal villi and crypts of *Fibcd1*^Tg^ mice ([Fig. 1, E and F](#fig1){ref-type="fig"}). Murine FIBCD1 (mFIBCD1) is a 459--amino acid protein that by sequence alignment shares 90.6% identity with its human orthologue ([@bib42]). As in humans, mFIBCD1 is predicted to be a type II transmembrane protein containing a C-terminal fibrinogen-related domain, which shares 97.2% identity with human FIBCD1 and includes a fully conserved S1 acetyl-group binding site previously shown to bind acetylated structures such as chitin ([@bib42]; [@bib47]; [@bib43]). We identified that soluble recombinant ectodomain of mFIBCD1 (mFIBCD1^Ecto^) assembled into homo-tetramers (Fig. S1 C) and bound chitin and other acetylated structures, in a Ca^2+^-dependent manner, through the conserved S1 acetyl-group binding site ([Fig. 1 G](#fig1){ref-type="fig"} and Fig. S1, D--G). Moreover, when expressed, full-length mFIBCD1 localized to the membrane and had the ability to internalize bound ligand (Fig. S1, H and I). At steady state, *Fibcd1*^Tg^ mice displayed no overt phenotype compared with WT littermates when assessed for breeding potential, offspring frequencies, weight development, or intestinal barrier integrity (Fig. S1, J--M). Moreover, IEC-specific expression of FIBCD1 did not influence the immune cell composition in the LP of SI (Fig. S1, N--P) or colon (Fig. S1, Q--S). Overexpression of *FIBCD1* in the A549 lung epithelial cell line in vitro has been shown to suppress genes associated with epithelial responses at steady state as well as upon stimulation with fungal cell wall components and a variety of TLR agonists ([@bib20]). Yet, when sort-purified CD45^−^CD326^+^ IECs from *Fibcd1*^Tg^ mice were assessed for the expression of a wide range of genes associated with mucus production (*Muc2* and *Muc5Ac*), cell adhesion/tight junction formation (*Cd326*, *Icam1*, *Zo1*, *Cldn1*, and *Cldn2*), immune responses (*Ccl2*, *Ccl20*, *Il-1b*, *Il-18*, *Il-25*, *Il-33*, and *Tslp*) and production of anti-microbial peptides (*Reg3a* and *Reg3g*), no significant differences were observed compared with WT littermates (Fig. S1, T--W). Collectively, these data suggest that *Fibcd1*^Tg^ mice are healthy with no aberrant phenotype, and although transgenic, they can serve as a suitable tool that recapitulates the in vivo expression of FIBCD1 in the human intestine.

To test the functional role of FIBCD1 expression on IECs in vivo, we employed the parasitic whipworm *Trichuris muris*, a widely used model of intestinal helminth infection that is transmitted through ingestion of chitin-containing embryonated *T. muris* eggs ([@bib37]; [@bib7]; [@bib21]). We identified that FIBCD1 recognized and specifically bound the chitin-rich polar plugs of *T. muris* eggs (Fig. S2 A). We further identified *T. muris* excretory-secretory (E/S) antigen, consisting of a mixture of immune-modulatory proteins, lipids, and chitinous carbohydrates ([@bib19]; [@bib9]; [@bib15]; [@bib12]), as potential ligands of FIBCD1 (Fig. S2 B). Immunity to *T. muris* is dependent on type 2 cytokine responses that promote IEC proliferation, goblet cell responses, and expulsion of the parasites ([@bib7]; [@bib21]). However, when we tested the role of FIBCD1 in immunity to *T. muris* infection, *Fibcd1*^Tg^ mice exhibited equivalent type 2 cytokine responses and protective immunity as compared with WT littermates (Fig. S2, C--J). Similarly, *Fibcd1*^Tg^ mice did not exhibit defects in type 2 immunity or parasite expulsion when infected with other chitin-containing helminth parasites, *Heligmosomoides polygyrus* or *Nippostrongylus brasiliensis* (Fig. S2, K--Q). Together, these data suggest that while FIBCD1 binds helminth-derived components that contain chitin in vitro, FIBCD1 is not required to modulate type 2 immunity following helminth infection.

Since FIBCD1 is a novel receptor of chitin capable of binding chitin-rich regions of *A. fumigatus* ([@bib20]) and recent studies have highlighted the importance of interactions between host and fungi present at barrier surfaces ([@bib17]; [@bib54]; [@bib25]), we tested whether IEC-restricted expression of FIBCD1 would influence the composition of the gut mycobiome. Initial characterization by quantitative PCR (qPCR) of the relative abundance of fungal 18S ribosomal DNA in WT and *Fibcd1*^Tg^ littermates cohoused in mixed litters did not reveal any significant changes in fungal burden ([Fig. 2 A](#fig2){ref-type="fig"}). However, following separation and 2 wk of additional housing based on genotype, we observed a significant reduction in the abundance of fungal 18S ribosomal DNA in *Fibcd1*^Tg^ mice compared with WT littermates ([Fig. 2 A](#fig2){ref-type="fig"}). To further characterize the impact of FIBCD1 on the composition of intestinal fungal communities, we performed high-throughput internal transcribed spacer 1 (ITS-1) sequencing analysis of fungal ribosomal DNA. ITS-1 sequencing revealed significant changes in the fungal composition in *Fibcd1*^Tg^ mice compared with WT littermates, where the abundance of species belonging to the *Saccharomycetaceae* family, dominated by the prevalent *Candida* genus, was significantly reduced in *Fibcd1*^Tg^ mice ([Fig. 2, B--E](#fig2){ref-type="fig"}). Like humans, mice are predominantly colonized with fungal species belonging to the *Ascomycota* phylum, particularly *Candida* spp., but mice exhibit a striking absence of *Candida albicans* and a prevalence of *Candida tropicalis* relative to humans ([@bib17]). In line with this and our ITS-1 sequencing data, we observed a significant reduction in the relative abundance of *Candida* spp. and specifically *C. tropicalis* in *Fibcd1*^Tg^ mice compared with WT littermates when assessed by qPCR ([Fig. 2, F and G](#fig2){ref-type="fig"}). Since bacteria and fungi may interact in the intestine, we also evaluated the bacterial composition of *Fibcd1*^Tg^ mice compared with WT littermates. Analysis by qPCR and sequencing of 16S bacterial ribosomal DNA did not identify FIBCD1-mediated changes to the composition of the bacterial microbiota (Fig. S2, R--V). Thus, we conclude that FIBCD1 selectively regulates the composition of the intestinal mycobiome.

![**Expression of FIBCD1 by IECs modulates the intestinal mycobiome and FIBCD1 binds chitin-containing fungi. (A)** Assessment of fungal burden (FungiQuant) relative to 16S in WT and *Fibcd1*^Tg^ (Tg) littermates cohoused (Co) or housed for additional 2 wk based on genotype (Geno; *n* = 15 samples per group). **(B)** PCoA ordination based on Bray--Curtis dissimilarities in colonic fungal OTUs (*n* = 4 samples per group). **(C)** Fungal composition of the 14 major genera in WT and Tg littermates (*n* = 4 samples per group). **(D and E)** Relative abundance of Saccharomycetaceae (family) and the abundant *Candida* (genus) in WT and Tg littermates quantified by ITS-1 sequencing (*n* = 4 samples per group). **(F and G)** Relative abundance of *Candida* spp. and *C. tropicalis* normalized to FungiQuant in WT and Tg littermates quantified by qPCR (*n* = 10 samples per group). **(H)** Representative fluorescence imaging of recombinant FIBCD1^FReD^ binding a proportion of live *C. tropicalis*. Blue, WGA; magenta, FIBCD1^FReD^. Scale bar, 10 µm. **(I)** Representative scatter plot and histogram of WGA^+^ *C. tropicalis* binding recombinant FIBCD1^FReD^. **(J)** Histograms and quantification of mean fluorescence intensity (MFI) demonstrating Ca^2+^-dependent and GlcNAc-specific binding of FIBCD1 to WGA^+^ *C. tropicalis* (*n* = 3 samples per group). Results shown in A--G are representative of two independently performed experiments with similar results. Data shown in H--J are representative of at least three independently performed experiments with similar results. Statistics: Data are presented as mean ± SEM where dots represent individual mice. Two-way ANOVA followed by Holm--Sidak post hoc test was used to analyze results in A, unpaired Student's *t* test was used to analyze data in D--G, and one-way ANOVA followed by Tukey post hoc test was used to analyze results in J. \*, P \< 0.05, \*\*, P \< 0.01, \*\*\*, P \< 0.001, and \*\*\*\*, P \< 0.0001. Max, maximum; SSC, side scatter.](JEM_20182244_Fig2){#fig2}

As FIBCD1 binds chitin-rich regions of the opportunistic pathogen *A. fumigatus* and *C. tropicalis* along with most fungal species contains chitin as a structural component of the cell wall ([@bib24]), we next investigated the ability of recombinant FIBCD1 to bind *C. tropicalis* in vitro. By fluorescence microscopy and flow cytometry, we observed specific binding of the fibrinogen-related domain of FIBCD1 (FIBCD1^FReD^) to a fraction of exponentially growing *C. tropicalis* ([Fig. 2, H--J](#fig2){ref-type="fig"}). Binding was found to be restricted to cells staining positive for wheat germ agglutinin (WGA), a chitin-binding lectin recognizing exposed chitin in growing fungi ([@bib39]; [@bib29]). Binding was Ca^2+^ dependent and was abolished in the presence of GlcNAc, confirming specific binding through the conserved S1 binding site. Collectively, these results indicate that FIBCD1 potentially modulates the gut mycobiome through direct recognition of chitin on gut-resident fungi.

To directly assess the impact of IEC-restricted expression of FIBCD1 on fungal colonization, we colonized antibiotic-treated mice with *C. tropicalis* ([Fig. 3 A](#fig3){ref-type="fig"}). Antibiotics were added to decrease the potential effects of commensal bacteria and create a niche for fungal outgrowth ([@bib25]). Colonization with a single-dose of *C. tropicalis* (2.5 × 10^7^ cells) resulted in a robust 91% colonization efficiency in WT mice, whereas *Fibcd1*^Tg^ littermates were significantly more resistant to colonization, displaying efficiencies \<65% ([Fig. 3 B](#fig3){ref-type="fig"}). Further, in colonized mice, we observed a highly significant reduction in *C. tropicalis* CFUs in *Fibcd1*^Tg^ mice compared with WT littermates, starting as early as 24 h after colonization ([Fig. 3 C](#fig3){ref-type="fig"}). Colonization with *C. tropicalis* has been shown to increase the number and ratio of IL-17--producing CD4^+^ T helper (Th) 17 cells in colonic LP ([@bib25]). Consistent with heightened *C. tropicalis* burdens, WT mice exhibited elevated colonic Th17 responses in the LP compared with *Fibcd1*^Tg^ littermates ([Fig. 3 D](#fig3){ref-type="fig"}). Taken together, these data indicate a rapid and specific role for FIBCD1 in limiting fungal colonization of the intestine independently of changes in the bacterial communities.

![**Expression of FIBCD1 by IECs limits colonization with *C. tropicalis* and maintains immune homeostasis. (A--D)** WT and *Fibcd1*^Tg^ (Tg) littermates were treated with cefoperazone in drinking water from day −3 and throughout the experiment. At day 0, mice were colonized by oral gavage with 2.5 × 10^7^ exponentially growing *C. tropicalis* (*C. trop*) or PBS as control. **(A)** Schematic representation of the colonization model. **(B)** Quantification of colonized vs. resistant mice after *C. tropicalis* colonization (WT *n* = 32; Tg *n* = 34). **(C)** Quantification of CFUs of *C. tropicalis* in feces from WT and Tg littermates during the course of the experiment (mean shown, *n* = 12 samples per group). **(D)** Scatter plots, frequencies, and absolute numbers of IL-17--producing CD4^+^ T cells in colonic LP at day 7 after colonization with *C. tropicalis* (*n* = 4--7 samples per group). Results shown in B are pooled from five independently performed experiments. Results shown in C are pooled from three independently performed experiments. Results shown in D are representative of three independently performed experiments with similar results. Statistics: Data are presented as mean ± SEM where dots represent individual mice. Fisher's exact test was used to analyze results in B, and two-way ANOVA followed by Holm--Sidak post hoc test was used to analyze results in C and D. \*, P \< 0.05, \*\*\*, P \< 0.001, and \*\*\*\*, P \< 0.0001.](JEM_20182244_Fig3){#fig3}

Since fungal dysbiosis has been associated with exacerbated inflammation in animal models of intestinal inflammation and in patients suffering from IBD ([@bib17]; [@bib27]; [@bib26]; [@bib30]; [@bib54]; [@bib44]; [@bib25]), we next investigated the potential role of IEC-restricted FIBCD1 expression in regulating intestinal inflammation using the dextran sodium sulfate (DSS)--induced model of intestinal damage and inflammation. When exposed to DSS in the drinking water, *Fibcd1*^Tg^ mice exhibited significantly reduced weight loss compared with WT littermates ([Fig. 4 A](#fig4){ref-type="fig"}). At the time of sacrifice, *Fibcd1*^Tg^ mice displayed significantly reduced colonic shortening and decreased intestinal inflammation compared with WT littermates ([Fig. 4, B and C](#fig4){ref-type="fig"}). Consistent with more severe disease, WT mice exhibited a significant increase in the absolute number and frequencies of Th17 cells, as well as infiltrating Ly6G^+^ neutrophils in colonic LP compared with *Fibcd1*^Tg^ littermates ([Fig. 4, D and E](#fig4){ref-type="fig"}; and Fig. S3, A and B). Increased inflammation was also associated with a significant increase of Ly6c^high^ inflammatory monocytes in WT mice compared with *Fibcd1*^Tg^ littermates, whereas the frequencies of regulatory T cells and innate lymphoid cells (ILCs) were unaffected by IEC-specific expression of FIBCD1 after DSS treatment (Fig. S3, C--E). Collectively, these data indicate that IEC-restricted expression of FIBCD1 reduces disease severity in DSS-induced intestinal inflammation.

![**Expression of FIBCD1 by IECs ameliorates DSS-induced intestinal inflammation. (A--G)** WT and *Fibcd1*^Tg^ (Tg) littermates were exposed to 2.5% (wt/vol) DSS in the drinking water for 7 d followed by 3 d of regular water. **(A)** Weight development of mice during the course of the experiment (mean shown, *n* = 4--12 mice per group). **(B)** Assessment of colonic shortening at time of sacrifice (*n* = 4--10 samples per group). **(C)** Degree of inflammation examined by histopathology (*n* = 3--6 samples per group). Representative H&E-stained sections are depicted. Scale bar, 200 µm. **(D)** Frequencies of CD45^+^CD3^+^CD4^+^IL-17^+^ T cells in colonic LP (*n* = 3--9 samples per group). **(E)** Frequencies of infiltrating CD45^+^CD11b^+^Ly6G^+^ neutrophils in colonic LP (*n* = 3--9 samples per group). **(F and G)** Quantification of relative fungal abundance (FungiQuant) and specific burden of *C. tropicalis* before DSS exposure and at time of sacrifice (*n* = 9 samples per group). **(H--J)** WT and Tg littermates treated with fluconazole before being exposed to 2.5% (wt/vol) DSS in the drinking water for 7 d followed by 3 d of regular water. Fluconazole treatment (0.5 g/liter in drinking water) was initiated day −3 and maintained throughout the experiment. ns, not significant. **(H)** Weight development of mice during the course of the experiment (mean shown, *n* = 10 samples per group). **(I)** Assessment of colonic shortening at time of sacrifice (*n* = 10 samples per group). **(J)** Quantification of total fungal abundance before DSS exposure and at time of sacrifice (*n* = 4--10 samples per group). **(K--M)** WT and Tg littermates were colonized with *C. tropicalis* as described in [Fig. 3 A](#fig3){ref-type="fig"} before being exposed to 2.5% (wt/vol) DSS in the drinking water for 7 d followed by 4 d of regular water. Cefoperazone treatment was maintained throughout the experiment. **(K)** Kaplan--Meier survival curves of WT and Tg littermates colonized with *C. tropicalis* followed by DSS treatment (*n* = 9--14 samples per group). **(L)** Weight development of *C. tropicalis*--colonized mice during the first 6 d of DSS treatment (mean shown, *n* = 21--23 samples per group). **(M)** Assessment of colon length at time of sacrifice (*n* = 9 samples per group). Results shown in A, H, K, and L are pooled from three independently performed experiments. Results shown in F, G, I, J, and M are pooled from two independently performed experiments. Results shown in B--E are representative of at least three independently performed experiments with similar results. Statistics: Data are presented as mean ± SEM where dots represent individual mice. Two-way ANOVA followed by Holm--Sidak post hoc test was used to analyze results in A--H, J, and L, unpaired Student's *t* test was used to analyze data in I and M, and log-rank Mantel--Cox test was used to analyze results in K. \*, P \< 0.05, \*\*, P \< 0.01, \*\*\*, P \< 0.001, and \*\*\*\*, P \< 0.0001.](JEM_20182244_Fig4){#fig4}

Since outgrowth of *Candida* spp. has been reported in DSS-driven intestinal inflammation ([@bib18]), we performed a quantitative assessment by qPCR of fungal burden, as well as the specific burden of prevalent *C. tropicalis* before and after DSS treatment. In WT mice, we observed a striking increase in general fungal abundance, as well as specific burden of *C. tropicalis* after DSS treatment, an increase that was significantly diminished in *Fibcd1*^Tg^ littermates ([Fig. 4, F and G](#fig4){ref-type="fig"}). Taken together, these data suggest that fungal outgrowth and in particular outgrowth of *C. tropicalis* may contribute to the severity of intestinal inflammation.

To further examine the potential significance of fungal outgrowth on disease severity, we next subjected WT and *Fibcd1*^Tg^ littermates to the antifungal drug fluconazole in combination with DSS exposure. Short-term administration of fluconazole, targeting most *Candida* spp. and other dimorphic fungi, has previously been shown to ameliorate DSS-induced inflammation in susceptible mice ([@bib17]; [@bib51]), whereas long-term treatment has been reported to increase DSS-induced disease severity ([@bib54]). Short-term treatment with fluconazole in mice exposed to DSS in the drinking water ameliorated disease severity in WT mice to levels comparable to *Fibcd1*^Tg^ littermates when assessed for weight loss and colon length ([Fig. 4, H and I](#fig4){ref-type="fig"}). Moreover, the DSS-driven induction of Th17 responses and neutrophil recruitment in fluconazole-treated mice were found to be comparable in WT and *Fibcd1*^Tg^ littermates (Fig. S3, F and G). Further, treatment with fluconazole resulted in a significant reduction of total fungal burden as well as specific burden of *C. tropicalis* in WT mice after exposure to DSS to levels comparable to *Fibcd1*^Tg^ littermates ([Fig. 4 J](#fig4){ref-type="fig"} and Fig. S3 H).

To assess whether FIBCD1-mediated alterations in the composition of gut-resident mycobiota directly impact the severity of intestinal inflammation observed during DSS-induced colitis, we colonized antibiotic-treated WT and *Fibcd1*^Tg^ littermates with *C. tropicalis* and subjected them to DSS treatment 7 d after colonization. WT mice colonized with *C. tropicalis* displayed a significantly increased mortality compared with colonized *Fibcd1*^Tg^ littermates, as well as a significant increased weight loss and reduced colon length when assessed after 6 d of DSS exposure ([Fig. 4, K--M](#fig4){ref-type="fig"}). Notably, only comparable levels of infiltrating Ly6G^+^ neutrophils were observed during early exposure to DSS in WT and *Fibcd1*^Tg^ littermates (Fig. S3 I). Yet, consistent with exacerbated disease, as well as increased burden of *C. tropicalis,* WT mice exhibited a significant increase in the frequency of Th17 cells in colonic LP compared with *Fibcd1*^Tg^ littermates (Fig. S3 J). Collectively, these data highlight a central role for intestinal fungi in modulating intestinal inflammation and illustrate a functional role for FIBCD1 as a novel pattern recognition receptor that can limit fungal-driven intestinal inflammation.

Emerging data indicate that alterations in the composition of the fungal mycobiome, coupled with fungal outgrowth and translocation across the epithelial barrier into the intestinal mucosa, are associated with prolonged antibiotic treatment, immunodeficiencies, and chronic inflammatory diseases like IBD ([@bib6]; [@bib27]; [@bib26]; [@bib30]; [@bib54]; [@bib44]). In this report, we identify a novel molecular pathway through which IECs lining the intestinal tract can recognize and control the mycobiota via chitin-binding FIBCD1. Specifically, IEC-intrinsic FIBCD1 expression can limit fungal colonization and fungal dysbiosis and reduce fungal-driven exacerbation of intestinal inflammation. These findings indicate that in addition to C-type lectin receptors, TLRs, nucleotide oligomerization domain (NOD)--like receptors, and other microbial sensors, FIBCD1 is a previously unknown evolutionarily conserved pattern recognition receptor that regulates mammalian-fungal interactions at the intestinal barrier surfaces.

Materials and methods {#s03}
=====================

Mice {#s04}
----

Mice overexpressing FIBCD1 specifically in the intestinal epithelium (*Fibcd1*^Tg^) were generated using the *Villin* promoter to drive transcription of *Fibcd1* following an approach described previously ([@bib36]). In brief, murine full-length *Fibcd1* was amplified from cDNA using the primers 5′-GTG​CGT​ACG​ATG​GTC​CAC​GAG​CGG​TG-3′ and 5′-GTG​ACG​CGT​CTA​GCG​GTC​CTC​ACG​GAC​C-3′, and inserted via BsiWI and MluI restriction sites into the pBS KS Villin MES vector kindly provided by S. Robine (Institute Curie, Paris, France). Following verification by sequencing, the prepared targeting vector was digested with SalI and purified before being injected into the pronuclei of fertilized oocytes of C57BL/6N mice (Taconic). Mice carrying the transgene were identified by PCR analysis of tail genomic DNA using the primers 5′-AAA​GCC​GGG​TGG​GCA​GGG​TA-3′ and 5′-GCT​GCC​CAC​GGT​CTT​CCA​CC-3′. Amplification was performed according to the following: 3 min at 95°C; 30 cycles of 95°C (30 s), 68°C (30 s), and 72°C (30 s); and a final 3 min elongation at 72°C. Stable *Fibcd1*^Tg^ lines were established by backcrossing transgene-carrying founder mice with C57BL/6J mice (Jackson Laboratory). *Fibcd1*^Tg^ littermates were identified among offspring and analyzed extensively by qPCR to ensure stable and singular integration of the transgene. All experiments in this study were conducted using *Fibcd1*^Tg/-^ mice (heterozygote for the transgene) derived from one transgenic founder backcrossed onto the C57BL/6J background for a minimum of eight generations (N8-13). All experiments were performed using sex- and age-matched littermates that were cohoused in litters of mixed genotypes if not specifically noted. All mice were maintained under specific pathogen--free conditions and were used in accordance with the Institutional Animal Care and Use Committee guidelines at Weill Cornell Medicine.

Recombinant FIBCD1 variants {#s05}
---------------------------

Recombinant variants of mouse FIBCD1 were produced by PCR using IMAGE clone (ID: 6848779) as template. Full-length mouse FIBCD1 (mFIBCD1^FL^) and the putative ectodomain of mouse FIBCD1 (mFIBCD1^Ecto^) were generated using the reverse primer 5′-TGG​TCT​TGC​TGG​AAG​ATG​G-3′ and the forward primers 5′-CTA​GCG​GTC​CTC​ACG​GAC-3′ and 5′-AAC​CAC​ACC​CAC​ACA​CCA​G-3′, respectively. The PCR fragments were cloned into the pcDNA/FRT/V5-His vector (mFIBCD1^FL^) or pSecTag/FRT/V5-His vector (mFIBCD1^Ecto^), according to the manufacturer's recommendations (Thermo Fisher Scientific). Selected point mutations were generated using the Quickchange XL Site-directed mutagenesis system according to the manufacturer's instructions (Agilent Technologies). Stable integration and expression of the mouse FIBCD1 variants in the mammalian Flp-in cell lines HEK293 or CHO (Thermo Fisher Scientific), as well as the expression and purification of the FIBCD1^FReD^ in insect cells were performed as described previously ([@bib42]; [@bib47]).

Characterization of recombinant variants of mouse FIBCD1 {#s06}
--------------------------------------------------------

Characterization of acetyl-group binding specificity by ELISA-based approaches, flow cytometry, and fluorescence confocal microscopy were performed as described previously ([@bib42]; [@bib47]) using the following antibodies: polyclonal chicken antibody raised against recombinant mFIBCD1^Ecto^ (Davids Biotechnology) was used for ELISA and fluorescence microscopy, and mouse anti-FIBCD1 monoclonal antibody raised against FIBCD1^FReD^ (clone 11--14-10) was used for flow cytometry. Pull-down experiments and Western blotting were performed as described previously ([@bib42]; [@bib47]), using polyclonal chicken antibody raised against recombinant mFIBCD1^Ecto^ (Davids Biotechnology) and alkaline-phosphatase conjugated anti-chicken IgG (Sigma-Aldrich).

Isolation of cells from mouse intestinal tissue and mesenteric LNs (MLNs) {#s07}
-------------------------------------------------------------------------

Intestinal tissue was removed, cleaned from remaining fat tissue, and opened longitudinally before it was washed in ice-cold PBS (Corning). Peyer's patches from SI were identified and eliminated. Dissociation of epithelial cells was performed by incubation on a shaker at 37°C in PBS containing 2% FBS, 5 mM EDTA, and 1 mM dithiothreitol (all from Thermo Fisher Scientific) twice for 15 min. After each step, samples were vortexed, and the epithelial cell fraction was passed through a 100 µm filter and collected. The remaining tissue was chopped into small pieces, and enzymatic digestion was performed on a shaker at 37°C for 45 min in RPMI 1640 medium (Corning) containing 5% FBS, 0.4 U/ml dispase (Thermo Fisher Scientific), 1 mg/ml collagenase III (Worthington), and 20 µg/ml DNaseI (Sigma-Aldrich). Dissociated leukocytes were passed through a 70 µm filter and collected. The remaining tissue (stromal fraction) was washed twice in ice-cold PBS and then homogenized in TRIzol. Collected epithelial cells and leukocytes were further enriched by a 20%/40% or 40%/80% Percoll gradient centrifugation (Sigma-Aldrich), respectively, before further processing.

MLNs were removed and cleaned from remaining fat tissue before being chopped into smaller pieces and incubated in RPMI medium containing 5% FBS, 20 µg/ml DNaseI and 0.3 mg/ml Liberase TL (Roche) for 20 min at 37°C. Following incubation specimens were mechanically dissociated and filtered through a 70 µm cell strainer.

Isolation of cells from human tissues {#s08}
-------------------------------------

Human organ donor material was obtained through an approved research protocol and material transfer agreement with LiveOnNY as described before ([@bib55]). Donors, three males and six females (LiveOnN donor ID: 309, 310, 311, 313, 318, 320, 335, 336, and 337; average weight ± SD, 82 ± 22 kg) were tested to be HIV^−^, hepatitis B^−^, and hepatitis C^−^, and did not have chronic disease or cancer. This work does not qualify as "human subject" research as confirmed by the institutional review board of Columbia University. Tissues were collected after the donor organs were flushed with preservation solution. Isolation and preparation of compartmentalized cell fractions (IECs, LP leukocytes, and remaining stroma) were performed as described previously ([@bib22]). Recovered IECs and LP leukocytes were stained with fluorescent-labeled antibodies and sort-purified. In addition, RNA was extracted from isolated IECs, LP leukocytes, remaining stroma, and whole unfractionated tissue using TRIzol.

Flow cytometry and cell sorting {#s09}
-------------------------------

Fc receptors were routinely saturated with anti-CD16/32-blocking antibody (mouse; BioLegend) or FcR Blocking Reagent (human; Miltenyi Biotec) before staining according to the manufacturer's instructions. Dead cells were excluded with Fixable Aqua Dead Cell Stain or DAPI (both from Thermo Fisher Scientific). Single-cell suspensions were incubated on ice in PBS containing 2% FBS and 1 mM EDTA supplemented with antibodies. For surface staining of mouse specimens or exclusion of lineage-positive cells, the following antibodies against CD4 (GK1.5), CD45 (30F11), CD3ε (145-2C11), B220 (RA3-6B2), CD11b (M1/70), CD11c (N418), Ly6G (1A8), CD326 (G8.8), FIBCD1 (11--14-10), CD19 (eBio1D3), CD5 (53--7.5), CD64 (X54-5/7.1), FcεRI (MAR-1), Ly6c (HK1.4), MHCII (M5/114.15.2), CD90.2 (30-H12), and CD127 (A7R34) were used. Intracellular staining with anti--IL-5 (TRFK5), IL-13 (eBio13A), IL-17 (eBio17B7), and IFNγ (XMG1.2) antibodies was performed using Cytofix/Cytoperm Fixation/Permeabilization Solution and Perm/Wash buffer (both from BD Biosciences). Intra-nuclear staining for FoxP3 (FJK-16s), RoRγt (B2D), GATA3 (TWAJ), and Tbet (eBio4B10) was performed using the Foxp3 transcription factor staining buffer set (eBioscience). Human samples were surface stained using antibodies against CD45 (HI30), CD326 (9C2), and FIBCD1 (HG-Hyb-12-2) before analysis. All antibodies used in flow cytometry analyses except anti-FIBCD1 antibodies were purchased from eBioscience, BioLegend, or BD Biosciences. All flow cytometry experiments were acquired using a five-laser, 18-color custom configuration Fortessa flow cytometer and the FACS Diva software (BD Biosciences) or sort-purified by using a five-laser, 18-color custom configuration FACSAria cell sorter (BD Biosciences). Collected data were analyzed with FlowJo V10.4.1 software (TreeStar).

Quantitative RT-PCR and PCR {#s10}
---------------------------

For transcriptional analyses, tissue samples and sorted cells were homogenized in TRIzol (Thermo Fisher Scientific) and stored at −80°C until processed. RNA was extracted with chloroform, and RNA concentration was determined using a Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific). Reverse transcription of total RNA was performed using the High Capacity cDNA Reverse Transcription kit according to the manufacturer's recommendations (Thermo Fisher Scientific). Quantification of expression was detected on a QuantStudio 6 Flex Real-Time PCR (Thermo Fisher Scientific) using the following TaqMan Gene Expression Assays (Applied Biosystems): mouse *Fibcd1* (Mm00619121_m1) and human *FIBCD1* (Hs00262524_m1); the following SYBR Green primers: *Muc2* (QT01060773), *Muc5ac* (QT01161104), *Cd326* (QT00248276), *Icam1* (QT00155078), *Cldn1* (QT00159278), *Cldn2* (QT01059212), *Ccl2* (QT00167832), *Ccl20* (QT02326394), *Il-1b* (QT01048355), *Il-18* (Qt00171129), *Il-25* (Qt00134645), *Il-33* (Qt00135170), and *Reg3g* (QT00147455) supplied by Qiagen; and the following SYBR Green primers: *Zo* (6678355a1), *Tslp* (10946698a1), and *Reg3a* (6755308a) obtained from Primerbank ([@bib53]). Gene expression was normalized as n-fold difference to mouse *Hprt1* (Mm00446968_m1) or human *HPRT1* (Hs02800695_m1) according to the cycling threshold. Analyses of the relative abundance of bacteria and fungi by qPCR was performed using the standard SYBR green protocol on the QuantStudio 6 Flex using the following primer pairs: *16S* (5′-ACT​CCT​ACG​GGA​GGC​AGC​AGT-3′/5′-ATT​ACC​GCG​GCT​GCT​GGC-3′; [@bib3]), *Bacteroides* (5′-GGT​TCT​GAG​AGG​AGG​TCC​C-3′/5′-GCT​GCC​TCC​CGT​AGG​AGT-3′; [@bib3]), Firmicutes (5′-GGAGYATGTGGTTTAATTCGAAGCA-3′/5′-AGCTGACGACAACCATGCAC-3′; [@bib14]), *SFB* (5′-AGG​AGG​AGT​CTG​CGG​CAC​ATT​AGC-3′/5′-TCC​CCA​CTG​CTG​CCT​CCC​GTA​G-3′; [@bib45]), *18S/FungiQuant* (5′-GGRAAACTCACCAGGTCCAG-3′/5′-GSWCTATCCCCAKCACGA-3′; [@bib31]), *Candida* spp. (5′-CCT​GTT​TGA​GCG​TCG​TTT-3′/5′-TCC​TCC​GCT​TAT​TGA​TAT-3′; [@bib41]), and *C. tropicalis* (5′-TTT​GGT​GGC​GGG​AGC​AAT​CCT-3′/5′-CGA​TGC​GAG​AAC​CAA​GAG​ATC​CGT-3′; [@bib17]). Relative abundance was standardized to input DNA using 16S as reference. Since DSS has been identified as an inhibitor of PCR, all samples from DSS models were supplemented with 0.01 g/liter spermine (Sigma-Aldrich) before analysis and run in log-fold dilutions to ensure correct quantification ([@bib23]).

Intestinal barrier integrity assay {#s11}
----------------------------------

Intestinal barrier integrity was assessed as previously described ([@bib2]). In brief, 8--10-wk-old *Fibcd1*^Tg^ and WT littermates were deprived of food and water for 4 h before being fed 200 µl of FITC-dextran (4 kD; Sigma-Aldrich) at 600 mg/kg by oral gavage. Blood was collected 4 h later by retro-orbital bleeding, and fluorescence intensity in the serum was measured (excitation, 490 nm; emission, 530 nm) using a Victor^3^ fluorometer (PerkinElmer). The serum concentration of FITC-dextran was subsequently determined from a standard curve of FITC-dextran serially diluted in mouse serum.

Helminth infections {#s12}
-------------------

*T. muris* was maintained and E/S antigens prepared as described in [@bib57]. Infection was established by administering 200 embryonated eggs by oral gavage, after which worm burden and immunological readouts were assessed at day 18 after infection. For *H. polygyrus* infection, 250 purified infective L3 larvae were administered by oral gavage, after which worm burden and immunological readouts were assessed at day 18 after infection. For *N. brasiliensis* infection, 500 purified infective L3 larvae were injected subcutaneously, after which worm burden and immunological readouts were accessed at day 7 after infection.

In vitro stimulation and ELISA {#s13}
------------------------------

For cytokine staining, bulk MLNs or colonic LP leukocytes were incubated in RPMI containing 10% FBS, 10 mM Hepes (Gibco), and 100 U/ml penicillin/100 µg/ml streptomycin (Gibco) in 96-well microtiter plates for 4 h at 37°C in 5% CO~2~. Incubation was performed in the presence of 1 µg/ml PMA, 1 µg/ml ionomycin, and 10 µg/ml brefeldin A (all from Sigma-Aldrich). For *T. muris* antigen stimulation, isolated MLNs (2 × 10^6^ cells) were cultured in 48-well microtiter plates for 48 h (37°C and 5% CO~2~) in 0.5 ml DMEM media (Corning) supplemented with 10% FBS, 10 mM Hepes, 100 U/ml penicillin, and 100 µg/ml streptomycin. Cells were stimulated with 50 µg/ml *T. muris* E/S antigen prepared according to [@bib57] or PBS serving as control. Detection of IL-4 (eBioscience), IL-5 (eBioscience), IL-13 (R&D Systems), and IFNγ (eBioscience) in the supernatants of cultured cells and total IgE in serum (eBioscience) was performed according to the manufacturer's instructions. Quantification *T. muris*--specific IgG1 in serum was performed using microtiter plates coated with 5 µg/ml *T. muris* E/S antigens followed by detection using anti-IgG1 antibodies (BD Biosciences) according to the manufacturer's recommendations.

Histology {#s14}
---------

Intestinal tissues were harvested and fixed in 4% paraformaldehyde (PFA; Bioworld) before paraffin embedding. From each specimen, two sections (spaced 500 µm apart) were obtained and used for the assessment. Periodic acid--Schiff (PAS) staining and H&E staining were performed by Idexx. Images were acquired using an inverted Nikon Eclipse Ti microscope. Quantification of goblet cell hyperplasia and inflammation was performed using ImageJ v1.49 software.

Fecal DNA isolation for ITS-1 and 16S sequencing {#s15}
------------------------------------------------

*Fibcd1*^Tg^ and WT littermates were cohoused until 6 wk of age before being separated in cages based on genotype. After 2 wk of housing based on genotype, two or three fecal pellets from each mouse were collected, snap-frozen in liquid nitrogen, and stored at −80°C until processed. Fecal DNA was isolated following lyticase (Sigma-Aldrich) treatment, bead-beating, and processing using the QIAmp Fast stool DNA kit (Qiagen) as described previously ([@bib46]).

16S rRNA bacterial sequencing {#s16}
-----------------------------

16S rRNA gene sequencing was performed using methods adapted from the National Institutes of Health Human Microbiome Project ([@bib35]). In brief, the 16S rDNA V4 region was amplified by PCR and sequenced on the MiSeq platform (Illumina) using a 2 × 250-bp paired-end protocol. The read pairs were demultiplexed based on unique molecular barcodes, and subsequently merged using USEARCH v7.0.1090 ([@bib10]), allowing zero mismatches and a minimum overlap of 50 bases. Merged reads were trimmed at the first base with Q5, after which a quality filter was applied discarding reads with \>0.05 expected errors. Merged and filtered 16S sequences were clustered into operational taxonomic units (OTUs) using the UPARSE algorithm ([@bib11]) with a similarity cutoff value of 97%. OTUs were mapped to a modified version of the SILVA Database containing only the 16S V4 region to determine taxonomies. Abundances were recovered by mapping the demultiplexed reads to the UPARSE OTUs. OTU tables were rarefied before calculation of Bray--Curtis dissimilarities, with rarefaction depth equal to either 10,000 reads or the minimum sample depth, whichever was largest. 16S sequencing data have been submitted to the National Center for Biotechnology Information Sequence Read Archive under Bioproject accession no. PRJNA560208.

ITS-1 fungal sequencing {#s17}
-----------------------

Deep sequencing of fungal ITS-1 region was performed essentially as described previously ([@bib25]). In brief, the fungal ITS-1 region was amplified by PCR and sequenced using a 2 × 300-bp paired-end protocol on the MiSeq platform (Illumina). All libraries were subjected to quality control using qPCR, DNA 1000 Bioanalyzer (Agilent), and Qubit (Life Technologies) to validate and quantitate library construction before preparing a Paired End flow cell. The generated raw FASTQ ITS-1 sequencing data were filtered to enrich for high-quality reads, removing the adapter sequence by cutadapt v1.4.1 or any reads that did not contain the proximal primer sequence ([@bib46]). Sequence reads were then quality-trimmed by truncating reads not having an average quality score of 20 (Q20) over a 3-bp sliding window and removing reads shorter than 100 bp ([@bib46]). These high-quality reads were then aligned to Targeted Host Fungi ITS-1 database, using BLAST v2.2.22 and the pick_otus.py pipeline in the QIIME v1.6 wrapper with an identity percentage ≥97% for OTU picking ([@bib1]). The alignment results were subsequently tabulated across all reads, using the accession identifier of the ITS reference sequences as surrogate OTUs and using a Perl script ([@bib46]). The R packages Phyloseq (1.16.2) and Vegan (2.4--3) were used for determining community properties such as Bray--Curtis index, principal coordinate analysis (PCoA) scaling of Bray--Curtis dissimilarities, and relative abundance at various taxonomic levels. R version 3.3.1 was used. ITS-1 sequencing data have been submitted to the National Center for Biotechnology Information Sequence Read Archive under Bioproject accession no. PRJNA560213.

Recognition and binding of FIBCD1 to *C. tropicalis* {#s18}
----------------------------------------------------

*C. tropicalis* (ATCC 750) was obtained from the American Type Culture Collection. *C. tropicalis* used for experiments was cultured in aerobic conditions at 37°C in Sabouraud Dextrose Broth (EMD Chemicals). Assessment of FIBCD1 binding was performed as follows: Overnight cultures of fungi were harvested, washed in PBS, and either fixed in 4% PFA for 1 h on ice or further processed alive. After PFA removal and washing, 2 × 10^7^ cells were stained with 1 µg FIBCD1^FReD^ ([@bib47]) in Tris-buffered saline containing 1% BSA supplemented with 5 mM CaCl~2~, 5 mM EDTA, or 50 mM GlcNAc (all from Sigma-Aldrich) for 2 h on ice. After extensive washing in corresponding binding buffers, detection of bound FIBCD1^FReD^ was performed in Tris-buffered saline (1% BSA and 5 mM CaCl~2~) using 1 µg/ml allophycocyanin-labeled anti-FIBCD1 antibody (clone 11--14-10) for 1 h on ice. Staining for exposed chitin was performed in parallel using 5 µg/ml Alexa Fluor 350--conjugated WGA (Thermo Fisher Scientific). Binding of FIBCD1 was visualized using a Nikon Eclipse Ti microscope (Nikon) or assessed by flow cytometry using a Fortessa flow cytometer and the FACS Diva software.

*C. tropicalis* colonization and fungal immune responses {#s19}
--------------------------------------------------------

Colonization with *C. tropicalis* was performed as described in [@bib25]. In brief, 6--8-wk-old cohoused *Fibcd1*^Tg^ and WT littermates were separated in cages based on genotype before the start of the experiment. 0.4 g/liter cefoperazone (Sigma-Aldrich) supplemented with 4 g/liter artificial sweetener (Sweet'n Low) was provided ad libitum in drinking water from day −3 precolonization and continued throughout the experiment. Mice were fed 2.5 × 10^7^ *C. tropicalis* by gavage at day 0, after which fungal colonization was assessed by CFUs daily until termination at indicated time points. Mice with CFU counts below 10^4^ colonies per gram feces were considered resistant to colonization. *Candida*-specific immune responses were assessed by flow cytometry in cells isolated from colon LP.

DSS-induced acute intestinal inflammation {#s20}
-----------------------------------------

Chemical induction of intestinal inflammation using DSS was performed using 8--10-wk-old sex-matched *Fibcd1*^Tg^ and WT littermates. In brief, acute intestinal inflammation was induced by oral administration of 2.5% (wt/vol) DSS (36--50 kD; MP Biomedicals) in drinking water for 7 d, followed by ordinary tap water. During this time period, the mice were weighted daily and subsequently sacrificed at day 10. At the time of sacrifice, fecal specimens and colon were collected for immunological analyses by ELISA, histology, qPCR, and flow cytometry. In *C. tropicalis*--colonized mice as well as corresponding controls, treatment with 0.4 mg/ml cefoperazone supplemented with 4 g/liter artificial sweetener (Sweet'n Low) was continued throughout the experiments. DSS treatment was initiated at day 8 after colonization in these experiments. 0.5 g/liter fluconazole (Sigma-Aldrich) supplemented with 4 g/liter artificial sweetener (Sweet'n Low) was provided ad libitum in drinking water from 3 d before exposure to DSS and continued throughout the experiments.

Histological assessment of inflammation {#s21}
---------------------------------------

Assessment of inflammation was performed essentially as described by [@bib33]. In brief, colonic sections were H&E-stained and assessed for disease severity by trained personnel blinded to treatment and genotype. Scoring was based on three parameters; severity of inflammation (0--3), crypt damage (0--5), and ulceration (0--3). The combined values were added to give a histological score between 0 and 11. Images were acquired using an inverted Nikon Eclipse Ti microscope.

Monoclonal antibodies raised against FIBCD1 {#s22}
-------------------------------------------

Mouse monoclonal anti-FIBCD1 antibody HG-HYB-12-2 was produced as previously described ([@bib42]). Mouse monoclonal anti-FIBCD1^FReD^ antibody clone 11--14-10 was produced by immunization of *Fibcd1*^−/−^ C57BL/6N mice. The mice were immunized twice with 20 µg of recombinant FIBCD1^FReD^ using GERBU as adjuvant (GERBU Biotechnik) with more than 2 wk between each immunization. The mice were boosted once by an intra-peritoneal injection with 20 µg recombinant FIBCD1^FReD^ without adjuvant 3 d before isolation of B cells. Hybridoma cells were produced by fusion between isolated B cells and myeloma cells and adapted for serum-free media. Secreted antibodies were purified using a protein G column on a fast protein liquid chromatography apparatus (ÄKTA). Generation of antibodies was performed under license from the Danish National Animal Experiments Inspectorate (reference no. 2012-15-2934-00076). Antibodies used for flow cytometry were labeled with allophycocyanin according to the manufacturer's recommendations (Thermo Fisher Scientific).

Statistical analysis {#s23}
--------------------

All statistical tests were performed with Prism v6.0 (GraphPad). Two-way ANOVA followed by Holm--Sidak post hoc test was used to compare experimental groups with two independent variables. One-way ANOVA followed by Tukey post hoc tests were applied to all experimental results with one independent variable in which more than two groups were compared. In analyses with only two groups and one independent variable, Student's *t* test was applied. All weight curves were analyzed by two-way repeated measures ANOVA followed by post hoc testing corrected for multiple comparisons using the Tukey method. For comparisons of Kaplan--Meier survival curves, log-rank (Mantel--Cox) tests were used. For analysis of *C. tropicalis* colonization efficiency, two-tailed Fisher's exact test was used. Error bars depict the SEM unless otherwise stated. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001; \*\*\*\*, P \< 0.0001.

Online supplemental material {#s24}
----------------------------

Fig. S1 shows expression of *Fibcd1* in mouse intestinal tissues and the initial characterization of transgenic mice specifically overexpressing FIBCD1 in the IECs. Fig. S2 shows that epithelial-specific expression of FIBCD1 does not influence immunity to helminth infection or changes the composition of gut bacteria. Fig. S3 expands upon the observed change to the immune cell composition in colon LP of WT and *Fibcd1*^Tg^ littermates in models of DSS-driven intestinal inflammation.
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